A Phase I, Single Center, Randomized, Open-Label Study Investigating the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics of GDC-0853 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Fenebrutinib (Primary) ; Rabeprazole
- Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus; Urticaria
- Focus Pharmacokinetics
- Sponsors Genentech
- 25 Sep 2018 Planned End Date changed from 22 Jun 2018 to 23 Jun 2017.
- 25 Sep 2018 Planned primary completion date changed from 22 Jun 2018 to 23 Jun 2017.
- 25 Sep 2018 Status changed from recruiting to completed.